GI Dynamics, Inc. Provides 2017 Business Outlook and 2016 Review
GI DYNAMICS, INC., APPOINTS OERN R. STUGE, MD, AMID CHANGE TO COMPANY’S BOARD OF DIRECTORS
GI Dynamics, Inc. Announces Completion of
A$1.5million Private Placement and Launch of Security Pu...
The GI Dynamics’ EndoBarrier® Gastrointestinal Liner System is used for the treatment of obese type 2 diabetes with BMI ≥ 30 kg/m2, or obese patients with BMI ≥ 30 kg/m2 with ≥ 1 comorbidities, or obese patients with BMI >35 kg/m2.
The liner is indicated for maximum implant duration of 12 months.
EndoBarrier is not approved for sale in the U.S. and is limited by federal law to investigational use only in the United States.
CAUTION: INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL (UNITED STATES) LAW TO INVESTIGATIONAL USE